Contravir Pharmaceuticals, Inc. Announces Uplisting to NASDAQ Capital Market
Sichenzia Ross Friedman Ference LLP Advises ContraVir Pharmaceuticals on NASDAQ Uplisting
New York, NY – February 27, 2015 – (Global Newswire) – Nationally recognized securities and
corporate law firm Sichenzia Ross Friedman Ference LLP announced today that the Firm has represented ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV), a biopharmaceutical company focused on the discovery and development of antiviral therapies, in the Company’s uplisting to the NASDAQ Capital Market. The uplisting is effective for trading on February 27, 2015 and ContraVir’s common stock will trade under its existing stock symbol: “CTRV”.
The Sichenzia Ross Friedman Ference LLP team was led by partner Jeffrey J. Fessler.
Visit SRF's LinkedIn page
Latest posts by Sichenzia Ross Ference LLP (see all)
- Sichenzia Ross Ference LLP Represents A.G.P/ Alliance Global Partners in $3.5 Million Public Offering for Safe-T Group Ltd. - November 6, 2019
- Sichenzia Ross Ference LLP Represents Document Security Systems, Inc. in a $1.8 Million Private Placement - November 5, 2019
- Sichenzia Ross Ference LLP Represents Aegis Capital Corp. in $3 Million Public Offering of Common Stock of Cocrystal Pharma, Inc. - November 4, 2019